Cargando…

Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch et al

Detalles Bibliográficos
Autores principales:	Chheda, Zinal S, Mueller, Sabine, Hegde, Bindu, Yamamichi, Akane, Butterfield, Lisa H, Okada, Hideho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10032395/ https://www.ncbi.nlm.nih.gov/pubmed/36944450 http://dx.doi.org/10.1136/jitc-2022-006617

Ejemplares similares

IMMU-31. PNOC007: H3.3K27M SPECIFIC PEPTIDE VACCINE COMBINED WITH POLY-ICLC FOR THE TREATMENT OF NEWLY DIAGNOSED HLA-A2+ H3.3K27M DIFFUSE MIDLINE GLIOMAS (DMG)
por: Mueller, Sabine, et al.
Publicado: (2020)

Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al
por: Immisch, Lena, et al.
Publicado: (2023)

H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2(+) patients with diffuse midline glioma
por: Immisch, Lena, et al.
Publicado: (2022)

Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy
por: Chheda, Zinal S., et al.
Publicado: (2018)

THER-05. GENETICALLY STABLE POLIOVIRUS VECTOR CARRYING H3.3K27M ANTIGEN FOR TREATMENT OF DIFFUSE MIDLINE GLIOMA BY INTRAMUSCULAR INJECTION
por: Mosaheb, Mubeen, et al.
Publicado: (2020)

Endogenous H3.3K27M derived peptide restricted to HLA-A∗02:01 is insufficient for immune-targeting in diffuse midline glioma
por: Wang, Stacie S., et al.
Publicado: (2023)

Novel and shared neoantigen for glioma T cell therapy derived from histone 3 variant H3.3 K27M mutation
por: Hou, Yafei, et al.
Publicado: (2015)

Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade Glioma
por: Gallus, Marco, et al.
Publicado: (2023)

MRI comparative study of diffuse midline glioma, H3 K27-altered and glioma in the midline without H3 K27-altered
por: Zhao, Ji-ping, et al.
Publicado: (2022)

HGG-33. Prognostic factors of H3K27M histone-mutant diffuse midline gliomas in patients ≤18yrs
por: Hu, Qingjun, et al.
Publicado: (2022)

Identification of Radiomic Signatures in Brain MRI Sequences T1 and T2 That Differentiate Tumor Regions of Midline Gliomas with H3.3K27M Mutation
por: Chilaca-Rosas, Maria-Fatima, et al.
Publicado: (2023)

Cooperativity between H3.3K27M and PDGFRA poses multiple therapeutic vulnerabilities in human iPSC-derived diffuse midline glioma avatars
por: Skinner, Kasey R., et al.
Publicado: (2023)

IMMU-23. A NOVEL MASS CYTOMETRY-BASED MULTI-PARAMETER CHARACTERIZATION OF NEOANTIGEN-REACTIVE CD8+ T-CELLS IN PATIENTS PARTICIPATING IN PNOC007 H3.3K27M PEPTIDE VACCINE CLINICAL TRIAL
por: Taitt, Jared, et al.
Publicado: (2020)

Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma
por: Chuntova, Pavlina, et al.
Publicado: (2022)

MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas
por: Abe, Hideaki, et al.
Publicado: (2020)

Diffuse midline gliomas, H3 K27M-mutant are associated with less peritumoral edema and contrast enhancement in comparison to glioblastomas, H3 K27M-wildtype of midline structures
por: Banan, Rouzbeh, et al.
Publicado: (2021)

Differences in the MRI Signature and ADC Values of Diffuse Midline Gliomas with H3 K27M Mutation Compared to Midline Glioblastomas
por: Raab, Peter, et al.
Publicado: (2022)

DIPG-76. HISTONE H3 PHOSPHORYLATION IN H3K27M MIDLINE GLIOMAS
por: Zhang, Liang, et al.
Publicado: (2020)

Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy
por: Chuntova, Pavlina, et al.
Publicado: (2019)

Fatal Postpartum Hemorrhage in Diffuse Midline Glioma with H3-K27M Mutation
por: Miyazaki, Takeshi, et al.
Publicado: (2019)

Prognostic Implication of Patient Age in H3K27M-Mutant Midline Gliomas
por: Vuong, Huy Gia, et al.
Publicado: (2022)

DIPG-42. Diffuse midline gliomas, H3K27-altered as an interdisciplinary challenge
por: Kammler, Gertrud, et al.
Publicado: (2022)

Radiotherapy and radio‐sensitization in H3 (K27M) ‐mutated diffuse midline gliomas
por: Liu, Chao, et al.
Publicado: (2023)

A H3K27M-targeted vaccine in adults with diffuse midline glioma
por: Grassl, Niklas, et al.
Publicado: (2023)

Dynamic susceptibility contrast perfusion-weighted and diffusion-weighted magnetic resonance imaging findings in pilocytic astrocytoma and H3.3 and H3.1 variant diffuse midline glioma, H3K27-altered
por: Kurokawa, Ryo, et al.
Publicado: (2023)

The H3.3K27M oncohistone antagonizes reprogramming in Drosophila
por: Ahmad, Kami, et al.
Publicado: (2021)

STAT3 as a biologically relevant target in H3K27M-mutant diffuse midline glioma
por: Anderson, Jacob B., et al.
Publicado: (2023)

Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant
por: Banan, Rouzbeh, et al.
Publicado: (2017)

Current Murine Models and New Developments in H3K27M Diffuse Midline Gliomas
por: Welby, John P., et al.
Publicado: (2019)

Morphological Spectrum and Survival Analysis of Diffuse Midline Glioma With H3K27M Mutation
por: Hassan, Usman, et al.
Publicado: (2021)

Diffuse midline glioma H3K27M mutation in adult: A case report
por: Bhattarai, Ayush Mohan, et al.
Publicado: (2022)

Diffuse midline glioma with H3 K27M-mutation in an 83-year-old woman
por: Low, Justin Thomas, et al.
Publicado: (2021)

Deep Learning for the Prediction of the Survival of Midline Diffuse Glioma with an H3K27M Alteration
por: Huang, Bowen, et al.
Publicado: (2023)

ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
por: Jackson, Evangeline R., et al.
Publicado: (2023)

Midline crossing and Slit responsiveness of commissural axons require USP33
por: Yuasa-Kawada, Junichi, et al.
Publicado: (2009)

STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma
por: Zhang, Liang, et al.
Publicado: (2022)

Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas
por: Schreck, Karisa C., et al.
Publicado: (2019)

Exploiting Gangliosides for the Therapy of Ewing’s Sarcoma and H3K27M-Mutant Diffuse Midline Glioma
por: Wingerter, Arthur, et al.
Publicado: (2021)

GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
por: Majzner, Robbie G., et al.
Publicado: (2022)

DIPG-44. H3K27-altered diffuse midline gliomas with secondary driver molecular alterations
por: Gestrich, Catherine, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j55moh4bv2a4m3nitqe0ds3vr4